Apoptosis is considered to be a major determinant of atherosclerotic plaque vulnerability and potential rupture [1] [2] [3] . Little is known, however, about the mechanisms that trigger apoptosis of vascular cells in atherosclerotic plaques. In human atherosclerotic specimens, apoptotic vascular smooth muscle cells (VSMC) were observed in areas with loss of pericellular adhesion 3 , indicating that pericellular proteolysis could be involved 4 . Proteases capable of degrading pericellular matrix components are indeed secreted by resident vascular cells and infiltrating inflammatory cells. 5 Components of the fibrinolytic system, including plasmin(ogen), plasminogen activators (either tissue-type, t-PA, predominantly expressed by VSMC 6-8 , or urokinase-type, u-PA, predominantly expressed by infiltrating macrophages), and plasminogen activator inhibitor-1 (PAI-1), [9] [10] [11] are present in human atherosclerotic lesions. The activity of plasmin promotes cell migration, regulates growth factor activity (e.g. Transforming Growth
Factor-β, TGF-β) 12 and induces extracellular matrix proteolysis, either directly, via degradation of adhesive glycoproteins, such as fibronectin 13 or laminin 14 or indirectly, via activation of matrix metalloproteinases 15 . Actually, it was recently demonstrated, using primary cultures of rat and human arterial VSMCs, that t-PA constitutively secreted by these cells can generate plasmin on the cell surface and induces thereby the proteolysis of extracellular matrix proteins, cell retraction and finally cell detachment leading to VSMC apoptosis 8 .
The fibrinolytic system plays a complex role in atherosclerosis, as assessed in experimental models using mice with targeted inactivation of its main components. 16 Thus, lack of PAI-1 in transgenic mice with combined apolipoprotein E and PAI-1 deficiencies (ApoE -/-:PAI-1 -/-) resulted in elevated plasmin levels, accompanied with extracellular matrix desorganization, increased accumulation of macrophages and a reduced density of myofibroblasts in advanced atherosclerotic lesions 17 . On the basis of the deleterious effect of plasmin on VSMC survival, 8 we sought to investigate if plasminogen activation by VSMCs ex vivo on the one hand, and the increased plasmin generation within ApoE -/-:PAI-1 -/aortic plaques in vivo on the other hand could lead to VSMC apoptosis. We demonstrate that aortic VSMC apoptosis can be induced ex vivo by plasminogen activation. In vivo, VSMC apoptosis and plasmin activity were colocalized within atherosclerotic plaques. This mechanism may contribute to plaque destabilization and rupture.
METHODS

Reagents and animals
Ten weeks old mice with targeted inactivation of the gene encoding PAI-1 (PAI-1 -/-) and wildtype (WT) mice of the same genetic background (75% C57Bl/6 and 25% 129SV) and of either sex were obtained as described elsewhere 18 .
Human or murine plasminogen, plasmin, and α2-antiplasmin were obtained as described 19, 20 .
Primary monoclonal antibodies used are described below. Secondary antibodies used were goat anti-mouse-Alexa fluor® 568 (Molecular Probes, Eugene, Oregon, USA) and biotinylated rabbit anti-mouse Ig (Dako, Glostrup, Denmark).
Animal models
For ex vivo experiments, WT and PAI-1 -/mice were anesthetized and exsanguinated by perfusion at physiological pressure via cardiac puncture with a 0.9% NaCl solution. The aorta was dissected, the adventitia was extruded as described 21 , and the aorta was cut first longitudinaly (to achieve de-endothelialization), and then transversely in 6 pieces of equal size.
These sections were incubated in a humidified CO 2 incubator at 37°C for 4 hours in Dulbecco's modified Eagle's Medium (without phenol red) containing 2 mM glutamine, 100 IU/ml penicillin and 0.1 mg/ml streptomycin, with and without 1.3 µM plasminogen, and in the absence or the presence of 1µM α2-antiplasmin. The aorta fragments were transferred to Jung tissue freezing medium™ (Leica Instruments, Nussloch, Germany) and snapfrozen in precooled 2-methyl butane.
For in vivo experiments, ApoE +/+ :PAI-1 -/mice were intercrossed with ApoE -/-:PAI-1 +/+ mice to generate breeding pairs with heterozygous deficiency of ApoE and PAI-1 (ApoE +/-:PAI-1 +/-), which sired ApoE -/-:PAI-1 -/mice and ApoE -/-:PAI-1 +/+ littermate offspring with a mixed genetic background of 87.5% C57Bl/6 and 12.5% 129/SvJ, as described 17 . Mice were kept on a regular chow diet for 5 weeks, and then fed a cholesterol /cholate rich diet for 25 weeks, as described 17 .
Aorta embedding procedures were previously described 17 .
For all surgical procedures, mice were anesthetized by intraperitoneal injection of Nembutal (60 mg/kg ; Abbott Laboratories, North Chicago, IL, USA). All procedures were approved by the University Ethical Committee (P03112) and were performed in accordance with the guidelines of the International Society on Thrombosis and Haemostasis 22 .
Protein assays
For immunoblotting of plasmin(ogen) and active caspase 3, equal protein amounts from whole protein extracts (from in vivo experiments) were electrophoresed on a 15% acrylamide gel, under reducing conditions. The nonspecific sites of the membranes were blocked with 10% non-fat dry milk in Tris Buffered Saline (TBS) containing 1% Tween 20 (TBST). The membranes were incubated with a rabbit anti-human/mouse active caspase 3 antibody (R&D systems) or a rabbit anti-murine plasmin(ogen) 23 antibody overnight at 4ºC in TBST containing 1% non-fat dry milk.
Then, the membranes were washed and incubated with an anti-rabbit peroxidase-conjugated secondary antibody in TBST containing 1% non-fat dry milk. The membranes were washed with TBST, followed by detection with enhanced chemiluminiscence (ECL kit, Amersham).
Fibrinolytic activity was monitored by fibrin overlay (containing traces of plasminogen, with and without aprotinin) of non-fixed 8-µm arterial cryostat sections at 37°C for 24 hours 24 .
Histological and immunohistochemical studies
Tissue sections (8 µm thick) were stained with hematoxylin-eosin under standard conditions.
The following primary antibodies were used: for immunodetection of plasmin-α2-antiplasmin complexes, 7 AP (a mouse monoclonal antibody that recognizes neoantigen epitopes in the complexes but neither free plasmin nor α2-antiplasmin 25 ), for plasmin(ogen) a rabbit anti-murine plasminogen/plasmin 23 , for active caspase 3 a rabbit anti-human/mouse active caspase 3 (R&D systems) and for VSMC detection a mouse anti-human smooth muscle actin (DAKO).
Biotinylated secondary antibodies were applied in combination with the Vectastain system (ABC kit, Vector Laboratories Inc, Burlingame, CA, USA), using the appropriate negative controls. Transmission electron microscopy was performed as described 26 .
Statistical analysis
The statistics were performed with the Statview 5.0 software. Results are expressed as mean ± SEM or median (range). Comparisons were made by one-way analysis of variance with Scheffe's F test, or Wilcoxon signed ranks, or Mann-Whitney U-test, as appropriate. Statistical significance was set at P < 0.05.
RESULTS
Aortic VSMC apoptosis parallels plasminogen activation ex vivo
In order to isolate the effect of plasminogen activation on VSMC apoptosis from other cellular components of the vascular wall, we performed ex vivo experiments on isolated aortic tunica media from WT and PAI-1 -/mice. The tunica media were incubated with plasminogen at 1.3 µM for 4 h, with or without 1 µM α2-antiplasmin. Plasmin generation developed faster in PAI-1 -/than in WT aortas, as assessed by in situ fibrin zymography ( Fig. 1A) . VSMC apoptotic levels, as assessed by TUNEL, was not significantly different between both genotypes in the absence of plasminogen (n=9, P=0.1). Following plasminogen activation, PAI-1 -/aortas displayed a fivefold increase in VSMC apoptosis (n= 9, P= 0.03) that was inhibited by α 2 -antiplasmin, thus suggesting a plasmin-dependent effect ( Fig. 1B-C) . In contrast, apoptotic levels in WT aortas remained unchanged following the incubation with plasminogen (n=9, P>0.99; Fig. 1 B-C) .
Increased plasmin generation and VSMC apoptosis in atherosclerotic plaques from ApoE -/-
:PAI-1 -/mice.
To investigate the involvement of the plasminogen activation system in apoptosis of vascular cells in vivo and its relevance for atherosclerosis, we analyzed atherosclerotic and nonatherosclerotic aorta fragments from ApoE -/-:PAI-1 +/+ and ApoE -/-:PAI-1 -/mice. In both genotypes, plasmin activity was increased in extracts from aortic areas with plaques, as compared to areas without plaques, being six-fold more abundant (n=4, P<0.05) in plaques from ApoE -/-:PAI-1 -/mice as compared to plaques from ApoE -/-:PAI-1 +/+ mice ( Fig. 2A, upper panel) . Activated caspase-3 ( Fig. 2A, lower panel) was barely detectable in areas without plaques, in either genotype (n=4, P= 0.96) but was concomitantly increased six-fold in plaques from ApoE -/-:PAI-1 -/mice (plaque vs non plaque, n=4, P= 0.003) but not in ApoE -/-:PAI-1 +/+ mice (n=4, P= 0.24). Similarly, caspase-3 activity levels were higher in plaques from ApoE -/-:PAI-1 -/as compared to plaques from ApoE -/-:PAI-1 +/+ mice (n=4, P= 0.04). In short, active caspase-3 levels paralleled plasmin levels in atherosclerotic plaques. Tissue section analysis confirmed that plasminogen activation as assessed by plasmin-α 2 -antiplasmin complexes (data not shown), plasmin detection ( Fig. 2B ) and apoptosis (activated caspase 3 in Fig. 2C , TUNEL in Fig. 2D and electron microscopy analysis in Fig. 2E ), were present within the aortic intima only in areas with plaques, in both genotypes. Apoptosis within atherosclerotic plaques was a patchy phenomenon, but apoptotic cells were mainly located in the fibrous cap and were predominantly foam-cells.
We used the TUNEL to quantitatively compare the VSMC index in plaques from both genotypes.
Since about 25 % of the examined areas did not contain α-actin positive cells, to overcome a potential bias, we calculated the VSMC apoptotic index as a ratio (apoptotic VSMC/ total VSMC)x100, each parameter being the average of the 18 values collected from the 18 areas (from 3 sections, 100 µm apart) evaluated per mouse. ApoE -/-:PAI-1 -/plaques had a significantly lower VSMC density (13±1% vs. 23±2%, P<0.05, n=5) but the total cellular density was not significantly different between both genotypes. Although the overall apoptotic cell density was not significantly increased in ApoE -/-:PAI-1 -/mice plaques, the VSMC apoptotic index was significantly higher within atherosclerotic plaques from ApoE -/-:PAI-1 -/-(1.5% (0-9.5), n=8) as compared to ApoE -/-:PAI-1 +/+ mice (0% (0-0.5), n=7, P<0.03). Averaging in each mouse the indices calculated in each individual area (i.e omitting areas without α-actin positive cells, where the apoptotic index could not be calculated) yielded similar trends (not shown).
DISCUSSION
Cell death by apoptosis is considered to be a major determinant of atherosclerotic plaque vulnerability [1] [2] [3] . VSMCs can stabilize atherosclerotic plaques by maintaining the tensile strength of the fibrous cap via the synthesis of collagen isoforms and protease inhibitors. VSMC apoptosis may therefore potentially contribute to the instability and rupture of plaques. Although apoptosis has been detected in human plaques, the mechanisms that trigger this apoptosis and its contribution to VSMC loss, remain unclear.
It has been reported that VSMCs in atherosclerotic lesions may undergo apoptosis in response to effectors secreted by infiltrating inflammatory cells. Macrophages, for instance, may contribute to VSMC apoptosis by direct cell-cell contact, Fas-L/Fas signaling, nitric oxide and TNF-α production 27, 28 . However, VSMC autocrine destruction has not been demonstrated as yet, although a study suggested that self autodestruction may occur via Fas-mediated apoptosis by relocating Fas-L to the VSMC surface. 29 t-PA, an other glycoprotein constitutively expressed by VSMCs 30 , can be located at the cell surface where it transforms plasminogen into plasmin, which triggers proteolysis-induced cell detachment and apoptosis. 8 The hypothesis that this sequence of reactions may be participating in the apoptosis of vascular cells on atherosclerotic plaques in vivo, was evaluated in this study. The well characterized ApoE -/atherosclerosis prone mouse model mimics several features of human atherosclerosis 31, 32 , including the lack of VSMC apoptosis in the normal media 1, 2, 35 . Moreover, apoptosis is a heterogeneous and patchy phenomenon in this murine model, as also observed in humans 2, 36 . The combined deficiency of PAI-1 with ApoE -/allows a better assessment of the effects of plasminogen activation on atherosclerosis progression in vivo while discarding possible direct effects of PAI-1 on apoptosis 33 34 . Indeed, in both genotypes VSMC apoptosis was undetectable in aortic areas without atherosclerotic plaques.
Corroborating previous in vitro studies 8 , our ex vivo experiments revealed that, in the presence of physiological circulating plasminogen concentrations, VSMC apoptosis was associated with plasmin generation in PAI-1 -/aortic tunica media. In the absence of plasminogen, similar apoptotic rates were observed in WT and PAI-1 -/-VSMCs, suggesting that PAI-1 is not a proapoptotic factor in this model. Furthermore, we recently showed that fibroblasts in two or three dimensional culture systems became resistant to plasminogen activation-induced cell detachment and apoptosis when transfected either with PAI-1 or protease-nexin-1; these serpins inhibited plasminogen activation at the cell surface and subsequent pericellular proteolysis 35 . These findings are in agreement with previous data indicating that addition of PAI-1 inhibited plasminogen activation-induced gel contraction and capillary regression, whereas anti-PAI-1 antibodies potentiated these processes 36 .
Expression of the main components of the plasminogen/plasmin system has been documented in the atherosclerotic arterial wall of mice and humans 9, 17 . To test whether this system may be involved in vivo in VSMC apoptosis within plaques, we have compared VSMC apoptosis in ApoE -/-:PAI-1 +/+ and ApoE -/-:PAI-1 -/mice. Our data show that PAI-1 deficiency is associated with strongly enhanced apoptosis within advanced atherosclerotic plaques in ApoE deficient mice, as assessed by active caspase 3 generation. Electron microscopy revealed that most apoptotic cells were foam cells, probably of macrophage and VSMC origin. Our TUNEL results suggest that among the plaque cells, VSMCs maybe particularly sensitive to plasmin-induced apoptosis, since the overall and non-VSMC apoptotic rates were not significantly different between both genotypes. In contrast, VSMCs were almost only detected within plaques from ApoE -/-:PAI-1 -/mice. Moreover, we observed an associated decrease in VSMC cell density in ApoE -/-:PAI-1 -/mice, whereas the overall cell density did not significantly differ between both genotypes. A similar decrease in VSMC content and increase in caspase activity, was also observed in the inflammatory region of human carotid atherosclerotic plaques as reported recently 37 .
The apoptosis observed in ApoE -/-:PAI-1 -/plaques appears to be dependent on plasminogen activation, as suggested by the six-fold higher plasmin activity detected in atherosclerotic extracts of ApoE -/-:PAI-1 -/as compared to ApoE -/-:PAI-1 +/+ mice, and by the colocalization of plasmin and active caspase 3 in situ. An extracellular pathway leading to plasmin induced cell detachment and apoptosis of VSMCs has recently been described. 8 A similar plasmin(ogen)-dependent cell detachment mechanism has also been described for retinal ganglion cells 38 , endothelial cells 36, 39 , fibroblasts 35 , and cerebrovascular smooth muscle cells 7 , thus suggesting that autocrine production of plasminogen activators by VSMCs and other cell types may induce apoptotic autodestruction by cell surface-formed plasmin. As in vitro studies have revealed that plaqueinfiltrating inflammatory cells may degrade pericellular matrix components 4 , it is possible that in our atherosclerotic plaque mouse model, paracrine expression of urokinase by macrophages may also contribute to vascular cell detachment and apoptosis. Of note, macrophages overexpressing urokinase show accelerated atherosclerosis in ApoE-/-mice and had elevated lesion proteolytic activity that may causes plaque rupture 40 . Other proteases (elastase, chymase, granzyme B, matrix metalloproteinases) secreted by macrophages, T-lymphocytes and mast cells, may also trigger apoptosis by breaking-down cell-extracellular matrix interactions 4 .
Plasmin may also activate growth factors such as latent TGF-β, which may induce VSMC apoptosis 41 . Interestingly, we found, in ApoE -/-:PAI-1 -/mice, more pronounced extracellular matrix disorganisation, proMMP activation, and activation of latent TGF-β, as compared to ApoE -/-:PAI-1 +/+ mice 17 .
Detection of cell apoptosis by TUNEL may have some potential limitations. Firstly, it is known that the TUNEL technique may overestimate the apoptotic rate, especially in highly proliferative cells 42 . However, the proliferation rate of VSMC is known to be low in advanced atherosclerotic plaques 2, 43, 44 . Comparing the two ApoE -/-:PAI-1 genotypes, we observed no significant background, and our VSMC apoptotic rates were comparable to those observed in other studies using stringent criteria to define apoptosis 42 . Secondly, VSMCs within atherosclerotic plaques may lose α-actin immunoreactivity, thus compromising identification of VSMC-derived foam cells and determination of the apoptotic rate 1, 42, 44 . However, active caspase 3 detection within atherosclerotic extracts corroborated our TUNEL data and, most importantly, it parallelled plasmin activity.
In summary, we have found that ex vivo plasmin generation may lead to apoptosis of murine VSMCs. In vivo, plasmin activity in atherosclerotic plaques was associated with VSMC apoptosis in ApoE deficient mice, suggesting that plasmin may induce VSMC apoptosis during atherogenesis. Bot et al. 45 reported that the serine protease inhibitor Serp-1 (which inhibits plasmin and plasminogen activators) impaired atherosclerotic lesion formation and stabilized plaques in ApoE -/mice. Therapeutic strategies aimed at preventing pericellular plasminogen activation might thus be beneficial to stabilize atherosclerotic plaques. 
ACKNOWLEDGMENTS
